2022
DOI: 10.1111/cea.14214
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and immunological data from chronic urticaria onset after mRNA SARS‐CoV‐2 vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
15
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1
1

Relationship

2
6

Authors

Journals

citations
Cited by 19 publications
(15 citation statements)
references
References 8 publications
0
15
0
Order By: Relevance
“…14 In particular, patients have developed CSU following vaccination with the BNT162b2 mRNA and ChAdOx1-S vaccines. [15][16][17] It is thought that the immunologic response to the vaccine stimulates the CSU, possibly by releasing suppressed histamine-releasing autoantibodies or by stimulating the production of anti-high-affinity IgE receptor α autoantibodies. 15 In the present study, the researchers excluded patients with a history of vaccination within 3 months from participating in the C-19-AU group to avoid including cases of vaccine-related AU.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…14 In particular, patients have developed CSU following vaccination with the BNT162b2 mRNA and ChAdOx1-S vaccines. [15][16][17] It is thought that the immunologic response to the vaccine stimulates the CSU, possibly by releasing suppressed histamine-releasing autoantibodies or by stimulating the production of anti-high-affinity IgE receptor α autoantibodies. 15 In the present study, the researchers excluded patients with a history of vaccination within 3 months from participating in the C-19-AU group to avoid including cases of vaccine-related AU.…”
Section: Discussionmentioning
confidence: 99%
“…Most of the cases were associated with BNT162b2 mRNA or AstraZeneca vaccines, and the median time of urticaria onset has been reported to range between 1 day and 3 months 14 . In particular, patients have developed CSU following vaccination with the BNT162b2 mRNA and ChAdOx1-S vaccines 15–17 . It is thought that the immunologic response to the vaccine stimulates the CSU, possibly by releasing suppressed histamine-releasing autoantibodies or by stimulating the production of anti-high-affinity IgE receptor α autoantibodies 15 .…”
Section: Discussionmentioning
confidence: 99%
“…1 Many chronic spontaneous urticaria (CSU) cases (recurrent wheals, angioedema, or both for more than 6 weeks 2 ) have been observed after the booster dose. 3 To assess whether a temporal association exists between COVID-19 vaccines and new-onset CSU, we compared the incidence rates of vaccine-related CSU in the canton of Vaud (CSU-Vaud) with all of Switzerland (CSU-Swiss).…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, CU is one of the skin disorders most severely affected by COVID-19, and it severely impairs CU patient care ( 10 , 11 ). Besides, what has caused much concern is the adverse event in which CU occurs secondary to the COVID-19 vaccine ( 12 , 13 ). These suggest that COVID-19 and CU are closely related, but hardly any further genetic research exists.…”
Section: Introductionmentioning
confidence: 99%